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Abstract
Background: It is unclear to what extent pre-clinical studies in genetically homogeneous animal models of
amyotrophic lateral sclerosis (ALS), an invariably fatal neurodegenerative disorder, can be informative of human
pathology. The disease modifying effects in animal models of most therapeutic compounds have not been
reproduced in patients. To advance therapeutics in ALS, we need easily accessible disease biomarkers which can
discriminate across the phenotypic variants observed in ALS patients and can bridge animal and human pathology.
Peripheral blood mononuclear cells alterations reflect the rate of progression of the disease representing an ideal
biological substrate for biomarkers discovery.
Methods: We have applied TMTcalibrator™, a novel tissue-enhanced bio fluid mass spectrometry technique, to
study the plasma proteome in ALS, using peripheral blood mononuclear cells as tissue calibrator. We have tested
slow and fast progressing SOD1G93A mouse models of ALS at a pre-symptomatic and symptomatic stage in
parallel with fast and slow progressing ALS patients at an early and late stage of the disease. Immunoassays were
used to retest the expression of relevant protein candidates.
Results: The biological features differentiating fast from slow progressing mouse model plasma proteomes were
different from those identified in human pathology, with only processes encompassing membrane trafficking with
translocation of GLUT4, innate immunity, acute phase response and cytoskeleton organization showing enrichment
in both species. Biological processes associated with senescence, RNA processing, cell stress and metabolism, major
histocompatibility complex-II linked immune-reactivity and apoptosis (early stage) were enriched specifically in fast
progressing ALS patients. Immunodetection confirmed regulation of the immunosenescence markers Galectin-3,
Integrin beta 3 and Transforming growth factor beta-1 in plasma from pre-symptomatic and symptomatic
transgenic animals while Apolipoprotein E differential plasma expression provided a good separation between fast
and slow progressing ALS patients.
Conclusions: These findings implicate immunosenescence and metabolism as novel targets for biomarkers and
therapeutic discovery and suggest immunomodulation as an early intervention. The variance observed in the
plasma proteomes may depend on different biological patterns of disease progression in human and animal
model.
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Background
Amyotrophic lateral sclerosis (ALS), a fatal neurodegener-
ative disorder, is a clinically heterogeneous condition
where survival can be less than a year or more than a dec-
ade from symptoms onset, making any assessment of
treatment response in clinical trials difficult in absence of
reliable estimates of prognosis [1]. A significant diagnostic
delay in ALS prevents early treatment reducing the pro-
spect of therapeutic success [2]. Mutant superoxide dis-
mutase 1 (SOD1G93A) transgenic mice models of ALS
are widely used as surrogates of human pathology in
pre-clinical research. A relatively uniform genetic back-
ground and the strictly controlled environmental and
breeding conditions make SOD1G93A transgenic animals
ideal models to investigate the disease pathobiology and
the pre-symptomatic disease stage [3, 4].
Experimental evidence suggests that the rate of disease
progression in ALS may be linked to the immunological
response to neuronal degeneration, which is reproduced
systemically by altered blood levels of cytokines, acute
phase reactants and by an early down-regulation of
FoxP3-positive T regulatory cells predominantly in pa-
tients with a faster disease progression [5, 6]. In
SOD1G93A transgenic mouse models of ALS, symptom-
atic disease can develop with a slow and fast progression
in C57 and 129Sv genetic backgrounds respectively (here
defined as Sym-SOD1C57 and Sym-SOD1129S). In these
SOD1G93A transgenic mice, impairment of the protein
quality control in the spinal cord and the activation of
the major histocompatibility complex I (MHCI) expres-
sion in axons and neuromuscular junctions are consid-
ered indices of fast disease progression [7, 8].
The inflammatory response in ALS co-exists with a state
of deranged lipid metabolism and altered total daily energy
expenditure [6, 9, 10], associated also with the effects of
genetic mutations of the TDP-43 and C9orf72 genes linked
to familial ALS [11–14]. Importantly, it is also acknowl-
edged that functionally competent and high
energy-demanding motor neurons are vulnerable to
chronic inflammation and changes in metabolism [15–17]
while aging, one of the main risk factors for ALS, may in-
crease neuronal vulnerability with a decline in cell glucose
uptake and mitochondrial energy production [18].
Over 50 randomized controlled clinical trials in ALS
have been unsuccessful, despite many compounds hav-
ing shown a disease-modifying effect in animal models
[19–21]. There is therefore a critical need to improve
translation of pre-clinical results into clinical trial out-
comes in ALS, through the identification of molecular
factors driving disease progression in humans and ro-
dents which can be used for phenotypic stratification
across species. To this end, a viable strategy is the mo-
lecular profiling of accessible biofluids and of Peripheral
Blood Mononuclear Cells (PBMC), central to many
aspects of the systemic immunological reaction to neu-
rodegeneration [22, 23]. TMTcalibrator™, an unbiased
proteomics method, is ideally placed to combine tissue
and fluid proteomics in a single experiment, providing
significant gains in sensitivity and a direct link between
protein expression in diseased tissue and in matched
fluids [24].
In this study, we have used TMTcalibrator™ to investigate
biological features which are regulated in plasma and are
also coherently expressed in matched PBMC samples from
fast and slow progressing ALS patients (defined as
ALS-Fast and ALS-Slow), at an early and late stage of the
disease, and used immunoassays to re-test the plasma ex-
pression of the same markers in a more extended cohort of
similarly stratified ALS patients. We have used the same
approach to test pre-symptomatic and symptomatic
SOD1G93A transgenic mouse models of ALS with a fast
(129Sv strain) and a slow (C57 strain) progression of the
disease. We have detected an early inflammatory and acute
phase response in both human and animal model, while
perturbed metabolism and an overall switch to cellular sen-
escence is seen in fast progressing human pathology. We
found only a partial overlap of the plasma/PBMC proteome




ALS patients and biological samples were selected from the
ALS biomarkers study biorepository (Ethical approval:
London and the City Research Ethics Committee 1 09/
H0703/27). Exclusion criteria were neuroinflammatory and
neurodegenerative comorbidities, recent mechanical injur-
ies and/or infections, systemic autoimmune disorders, can-
cer, pro-thrombotic states, family history of ALS or
frontotemporal dementia (FTD) as well as known genetic
mutation linked to ALS or FTD. The Functional Rating
Scale-Revised (ALSFRS-R; range 1 to 48, with increasing
levels of neurological impairment with lower scores) was
used to define the level of neurological impairment, with
early ALS corresponding to a score > 40 and late ALS < 35.
Disease progression to last visit (PRL) was calculated as “48
- ALSFRS-R at the last visit, divided for disease duration
from onset to the last visit in months” (fast ALS progres-
sion: PRL > 0.7; slow ALS progression: PRL < 0.5) [6] .
Animal models
Female superoxide dismutase 1 (SOD1) transgenic mice
with a G93A mutation in a C57BL/6JOlaHsd
(C57SOD1G93A) and in a 129SvHsd (129SvSOD1G93A)
genetic background and wild-type female littermates (de-
fined as WTC57 and WT129Sv) were used in this study
(Jackson Laboratories, B6SJL-TgNSOD-1-SOD1G93A-1-
Gur). The development of the symptomatic stage of the
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disease differed significantly in the two SOD1G93A trans-
genic mouse strains, with regards to disease onset and dur-
ation [8, 25]. In this study, fast developing symptomatic
SOD1G93A transgenic mice are defined as
Sym-SOD1129Sv (129Sv pre-symptomatic mice as
Pre-SOD1129Sv), while slow symptomatic progressing mice
as Sym-SOD1C57 (C57 pre-symptomatic mice as
Pre-SOD1C57). SOD1G93A transgenic animals expressed
20 copies of the human Gly93Ala SOD1 gene substitution
in the C57OlaHsd and 129SvHsd backgrounds for more
than 30 and 10 generations respectively. Mice were main-
tained in a specific pathogen-free environment (21 °C
temperature, 10% relative humidity in a 12 h of light/dark
cycle) with food/water supplied ad libitum and adaptations
for animals with a substantial motor impairment. Mice of
both strains were considered in a symptomatic stage when
they exhibited a 50% decrease in latency of grip strength
and a 45% body weight decline from the peak values in the
pre-symptomatic stage [26]. Plasma samples from Wild
type (WT) animals used in the re-test experiments were
obtained at the same time of blood collection from both
pre-symptomatic and symptomatic SOD1G93A transgenic
animal models.
Sample collection, plasma and mononuclear cell
extraction and processing
18 ml blood were collected in EDTA tubes and centri-
fuged at 800 g for 10 min at room temperature. Plasma
was recovered and centrifuged at 3500 rpm for 10 min
and stored at − 80 °C. Plasma samples were albumin and
IgG depleted (ProteoPrep® Immunoaffinity kit). PBMC
were isolated by density-gradient 2000 rpm centrifuga-
tion for 40 min at 20 °C using Lymphoprep™ (Alere) and
subsequently washed in Dulbecco’s phosphate-buffered
saline (Gibco). PBMC pellets were stored at − 80 °C in a
freezing solution (10% DMSO in foetal bovine serum).
After 24 h, PBMC aliquots were transferred into liquid
nitrogen. PBMC samples were thawed at 37 °C and
re-suspended in 10 ml warm (37 °C) Dulbecco phos-
phate buffer. Cell suspension was centrifuged at room
temperature and the pellet was re-suspended in 100 μl
of lysis buffer (8 M urea, 75 mM NaCl, 50 mM Tris,
pH 8.2, protease inhibitors cocktail, cOmplete™, Mini
Protease Inhibitor Co, Sigma). Blood was collected from
mice cheek and diluted in 3 ml medium (2.5 mM EDTA,
2% FBS in PBS) for PBMC and plasma fractions isolation
as reported above. PBMC samples were lysed, sonicated
and stored at − 80 °C.
In-solution tryptic digest, tandem mass tag (TMT®)
labelling and TMT calibrator™
Protein quantification was carried out using a Bradford
Protein Assay (Bio Rad). 100 μg (30 μg for mice) protein
from depleted plasma and 1 mg (750 μg for mice) from
the PBMC pool were dried down in a vacuum centrifuge
(SpeedVac, Thermo Scientific). Following solubilisation
and denaturation in 100 mM Triethylammonium bicar-
bonate (TEAB)/0.1% (w/v) SDS), samples were reduced
with 1 mM tris (2-carboxyethyl) phosphine 10 (TCEP) at
55 °C for 60 min and alkylated with 7.5 mM iodoaceta-
mide at room temperature (RT) for 60 min. Trypsin
(MS grade, Promega) was added at a 1:25 (w/w) ratio to
total protein and incubated at 37 °C overnight. Digestion
products were labelled with TMT®10plex reagents
(Thermo Scientific) and incubated at RT for 60 min. Six
of the 10 isobaric TMT® reagents were used to label in-
dividual plasma samples and the total amount of PBMC
protein pool was divided among the remaining 4 TMT
channels (the four-point calibrator) comprising 1/21, 4/
21, 6/21 and 10/21 total protein respectively. To quench
the TMT® reaction, 0.25% hydroxylamine was added.
The samples were then combined to form the analytical
10plex sets, desalted in RP18 columns and dried under
vacuum. The human plasma samples were divided into
four TMT®10plex sets, two for the early and two for the
late time point plasma samples. Each set contained three
ALS-Fast and three ALS-Slow plasma samples in com-
bination with the four-point PBMC pool lysate (human
PBMC representing all the conditions and phenotypic
variants under investigation) used as calibrator
(Table 1B). The same experimental design was applied
to the animal model study, where four different
TMT®10plex sets were used to compare 24 samples in
total. Two TMT®10plex sets included samples from
transgenic mice, one for Pre-SOD1129Sv and
Pre-SOD1C57, and the other one for Sym-SOD1129Sv
and Sym-SOD1C57 (n = 3 for each genetic background
plus 4 channels in each set for the mouse PBMC pool
calibrator). The remaining two TMT®10plex sets in-
cluded plasma samples from the equivalent Wild type
(WT) animals for both 129Sv and C57genetic back-
grounds (n = 3 per group, plus 4 channels in each set for
the mouse PBMC pool calibrator), collected at the same
time blood was taken from pre-symptomatic and symp-
tomatic animal (Additional file 1: Figure S1 A, shows
sample distribution across TMT®10plexes).
Strong cation exchange (SCX) fractionation and liquid
chromatography tandem mass spectrometry (LC-MS/MS)
Each analytical 10plex sample was reconstituted and
loaded onto a Polysulfoethyl-A column (4.6 × 100 mm,
5 μm, 200 Å, PolyLC) attached to a Waters 2695 HPLC.
Quantitative analysis was performed using an Orbitrap
Fusion™ Tribrid™ mass spectrometer in positive ion
mode with an EASY nLC1000 system and 50 cm
EASY-Spray column (all Thermo Scientific). More de-
tails on the SCX and LC-MS/MS methodologies are re-
ported in the Additional file 2.
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Mass spectrometry analysis and computational
proteomics
All plasma samples and pooled PBMC lysates used as
tissue calibrator passed sample quality control protocols
(data not shown) and were divided into four
TMT®10plex sets. All mass spectrometry files were
inspected independently and passed internal quality con-
trol metrics (data not shown). Outputs of computational
proteomics from the 40 raw data files from each
TMT®10plex study (human and animal model study)
were assembled into a single dataset and processed by
Proteome Sciences’ proprietary workflows for TMTcali-
brator™ including data integration (CalDIT),
pre-processing and feature selection (FeaST). Normal-
ised quantitative data were provided for all plasma pep-
tides channels as a ratio against the calculated mid-point
value of the PBMC calibrator channels (see Additional
file 1: Figure S1 describing the experimental workflow).
Peptide identification and quantification
For each experiment, raw mass spectrometry data files
were submitted to Proteome Discoverer (PD) v1.4
(Thermo Scientific), using the Spectrum Files node. The
spectrum selector was set to its default values while the
SEQUEST-HT node was set to search data against the
human or mouse (supplemented with the human SOD1
sequence) FASTA UniProtKB and Swiss-Prot database
respectively. A more detailed description of the peptide
identification and quantification process is reported in
Additional file 2.
Data assembly, pre-processing and normalisation
In the first step of the CalDIT workflow, reporter ion in-
tensities were corrected to remove the contribution of
signals from adjacent reporter ion channels. Subse-
quently, within each mass spectrometry run, intensity
values across the four calibrant channels (129C, 130 N,
130C, 131) were normalised (median-scaling) and, for
each peptide spectrum match (PSM), a reference inten-
sity value was calculated based on the calibrant intensity
distribution. This reference value was then used to cal-
culate Log2-transformed PSM ratio values for each of
the experimental channels, resulting in lower variance
between PSM-level quantifications of the same peptide
sequence at different points of the elution profile, or MS
runs. To generate peptide expression (ratio) values, me-
dian values were then computed across quantified PSMs
of the same peptide sequence.
In the first step of the FeaST workflow, peptides with
more than ~ 35% missing quantitative values within an
experimental group (i.e. ALS-Fast-Early; ALS-Fast-Late;
ALS-Slow-Early; ALS-Slow-Late) were removed from
Table 1 Demographics and clinical characteristics of ALS (A,B,C) and healthy control (D) individuals included in the discovery
proteomics (A, B) and in the re-test immunoassays (C, D)
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3 M / 3F 61.3 (48–67) 1.5 (1–1.9) 20.5 (11–32) 10.2
(5–19)
13.8 (7–22) 3 limb /3 bulbar
B. DISCOVERY EXPERIMENT: ALS PBMC
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C. RE-TEST EXPERIMENT: ALS PLASMA SAMPLES
ALS type ALSRS-R Gender
M/F
Age at onset (years) PRL Time from onset























13 limb /11 bulbar
D. RE-TEST EXPERIMENT: HEALTHY
CONTROLS PLASMA SAMPLES
n = 29 Gender M/F Age at sampling (years)
8 M / 17F 60.9 (50.8–73)
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subsequent analysis. Remaining peptides, with values
below the percentage threshold, were replaced by values
imputed using the k-nearest neighbours (n = 2) imput-
ation method, applied to samples within each experi-
mental group. In order to reduce the batch effect
created by the use of multiple TMT®10 plexes, a
LIMMA-based batch effect correction procedure was
applied (Additional file 1: Figure S2), using a linear
model constructed on the TMT® 10plex batch number
and TMT® channel and specifying the experimental
groups (PCA before batch effect correction Additional
file 1: Figure S2). For protein-level analysis, the same
procedure was applied in a parallel analysis and, subse-
quently, expression values were computed by averaging
(trimmed mean, trim factor: 0.2) ratios of all
non-phosphorylated peptides which matched uniquely
to the gene identifier.
Two quality control metrics per sample were calcu-
lated: the median (measure of central tendency) and the
inter-quartile range (IQR), measure of scale, using pep-
tide and protein distributions. A sample was considered
as a strong outlier if either QC metric value was more
than three standard deviations from the overall mean.
Immunoassays
Expression analysis of 5 protein candidates in mouse
and human plasma samples was undertaken by
enzyme-linked immunosorbent assay (ELISA) using
commercial kits, a electrochemiluminescence (ECL)--
based Meso Scale Discovery (MSD) platform and by
Western blot. Plasma samples were processed, aliquoted
and frozen at − 80 °C within 1 h from blood collection,
according to standard consensus procedures. ECL-MSD
was used to quantify Apolipoprotein E (APOE; R-PLEX
Antibody Set F212I), Galectine-3 (R-PLEX Antibody Set
F214F) and transforming growth factor beta-1 (TGFB1;
U-PLEX kit K151XWK), in human and mouse plasma,
and Apolipoprotein A1 (ApoA1; R-PLEX Antibody Set
F21PR) in human. A commercial ELISA was used to
analyse ITGB3 and Apo A1 in mouse plasma (Biorbyt
orb408222 and Abbexa abx254777 respectively) as well
ITGB3 in human plasma (Biorbyt orb407522). Stan-
dards, primary and secondary antibodies, detection
range including lower and upper limits of detection were
specified in the manufacturer’s conditions. Plasma sam-
ples from Wild-type (WT) and SOD1G93A transgenic
mice (both pre-symptomatic and symptomatic), from
ALS-Fast, ALS-Slow and healthy controls were equally
distributed on each plate and measured in duplicate.
Each plate contained a target-specific calibrator: Apoli-
poprotein A1 (APOA1: 0–1,000,000 pg/ml for human
and 7.81-500 ng/ml for mouse); Apolipoprotein E
(APOE: 0–200,000 pg/ml); Galectin-3 (03,000 pg/ml),
TGFB1 (0–56,600 pg/ml) and ITGB3 (125–8000 pg/ml
for human 62.5-4000 pg/ml for mice).
For Western blot analysis of ITGB3, 40 μg of
albumin-depleted proteins were diluted in Laemmli buf-
fer and loaded onto 10% acrylamide gels. After electro-
phoresis, proteins were transferred onto nitrocellulose
membranes and blocked with Tris buffered saline 0.1%
Tween (TBS-T) containing 5% non-fat dry milk powder
and − 20 for 1 h at room temperature. Membranes were
then incubated overnight with rabbit anti-Integrin β3
antibody 1:1000 (Integrin β3, D7X3P XP® Rabbit mAb
#13166. Cell Signaling Technology, Inc.) and with
anti-Galectin-3 antibody (Mouse monoclonal Galectin 3
ab2785, Abcam Ltd.) in TBS-T (0.1%) containing 5% bo-
vine serum albumin (BSA) and further incubated with
horseradish peroxidase (HRP)-conjugated swine
anti-rabbit 1:2500 (Dako) as secondary antibody in
TBS-T (0.1%) containing 5% BSA. Enhanced chemilu-
minescence (ECL kit; GE Healthcare), the ChemiDoc
XRS+ imaging system and the image lab 5.2.1 (Bio-Rad)
software were used for signal detection acquisition and
analysis.
Statistical analysis and data mining
All statistical methods applied for the proteomic data ana-
lysis were performed using an in-house workflow called
FeaST, developed in R statistical programming environ-
ment. Principal component analysis (PCA) score and
loading plots were generated to study the variance struc-
ture of the data sets, indicating technical and biological
factors and the influence of each step in the data
pre-processing and normalisation workflow. Multifactorial
linear modelling (LIMMA) was applied to determine sig-
nificantly regulated features (peptides or proteins), using
the following linear model: logRatio ~ Class + Age + Stage
+ Group (ALS/Control). Log2 fold changes (logFC) and
p-values were calculated for all peptides and proteins that
passed the filtering criteria described (above). The signifi-
cance criterion α was standardly set to 0.05 to consider a
feature as “regulated”. Multiple testing was performed
using a Benjamini-Hochberg correction.
Proteome Sciences’ proprietary workflows for func-
tional analysis (FAT) were used to identify differences
among phenotypic variants in biological processes ex-
tracted from plasma proteomes. Significance of enrich-
ment was evaluated based on the results of Fisher’s
Exact Test and multiple test corrections were applied
(Benjamini-Hochberg). Functional terms used in this
analysis included Gene Ontology Biological Processes
and Reactome Pathways. Human and mouse-specific an-
notations were extracted from publicly-available data re-
positories. A minimum of two matched gene names was
required and terms were considered significant for a
3-group comparison.
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For the immunoassay data, statistical analysis was
performed using GraphPad Prism 6. Continuous vari-
ables were presented in median (interquartile range)
and nonparametric analysis for group comparisons
(with Dunn’s multiple comparisons test) as well as
correlation analysis were applied. We used log rank
analysis (Mantel-Cox test) to compare survival (fixed
date was used to censor data for survival analysis).
Receiver operating characteristic curve analysis was
used to assess assay sensitivity/specificity and diagnos-
tic performance. A p value of less than 0.05 was con-
sidered statistically significant.
We have used a RNA-Seq transcriptome and splicing
database of glia, neurons and vascular cells of the cerebral
cortex to look at cell type-specific expression in the central




17 patients with a diagnosis of possible, probable,
laboratory-supported and definite ALS according to the El
Escorial criteria [27] were enrolled in the discovery study
(demographic and clinical features reported in Table 1A,
B). Plasma samples from 12 of these, including six
ALS-Fast (progression rate to last visit (PRL) > 0.7; male/
female ratio 3/3, average age at disease onset 61.7, (48–67;
average disease duration to death or last visit 20.5 months
(11–32)) and six with a slow rate of progression (PRL <
0.5; 5 male/1 female, average age at disease onset 58.1,
35–71; average disease duration to death or last visit
107 months (97, 254)) were included in the exploratory
proteomics as analytical samples, while PBMC samples
isolated from blood donated by the remaining five patients
were used in the tissue calibrant channels (PRL range:
0.023–2.5; three male / two female, average age at disease
onset 65.8, 57–68), (Table 1).
Blood samples from an additional cohort of 47 ALS
patients, including 24 ALS-Fast and 23 ALS-Slow, and
29 healthy age and gender-matched controls were used
to re-test plasma expression of selected protein candi-
dates using immunodetection. The average age of dis-
ease onset among the ALS sub-groups was comparable
to the average age of sampling in the healthy control
group (Table 1C, D). The most common genetic muta-
tions linked to familial ALS were excluded and all ALS
patients had plasma CRP and ferritin levels within nor-
mal limits at the time of sampling (normal values: CRP
< 5 mg/L; ferritin 10–160 μg/L) [6].
The ALS functional rating scale revised (ALSFRS-R; 1 to
48, higher level of neurological disability with lower score)
was used to define early (ALSFRS-R ≥ 40) and late
(ALSFRS-R ≤ 35) time points in the ALS cohort used for
the discovery experiment. ALS patients were stratified
according to disease progression rate to last visit (PRL: 48
minus the ALSFRS-R score at the last visit, divided per dis-
ease duration from onset in months) in slow (PRL < 0.5)
and fast (PRL > 0.7). PBMC samples were extracted from
blood taken from 5 ALS patients with a variable rate of dis-
ease progression (B). Age at onset and gender for both pa-
tients and healthy matched controls are also reported. All
individuals belonged to the same ethnic group (Caucasian;
except for one patients who was of Asian ethnicity). Dur-
ation of the disease from onset of first symptoms (e.g.
weakness or speech impairment) to both sampling time
and death/last visit is reported. For each sub-group, values
are reported as mean (average).
Exploratory analysis using the feature selection tool
(FeaST)
Differentially regulated plasma protein signatures across
the four phenotypic variants were analysed using principal
component analysis (PCA), as illustrated in Fig. 1a. The
strongest driver of variance in the data matrix was stage of
disease (early vs. late), which was captured along the first
principal component (Fig. 1a: x-axis) and accounted for ap-
proximately 36% of total variance. The rate of disease pro-
gression was defined by the second principal component
(Fig. 1a: y-axis) and accounted for 15% of total variance
(Fig. 1b, c and d).
Functional analysis
Proteome Sciences’ proprietary tool for functional analysis
(FAT) was used to identify significantly enriched pathways
and biological processes in the human and mouse proteo-
mics data. A cross-sectional analysis was undertaken at the
early (Fig. 2) and late (Additional file 1: Table S1) time
points individually using fast vs slow progressing ALS pa-
tients as terms of comparison. Fast and slow ALS pheno-
typic variants were also analysed separately in a
longitudinal study, comparing early and late time points
(Additional file 1: Table S1, (2–3)). The same analytical ap-
proach was used to process data from pre-symptomatic
and symptomatic fast and slow progressing SOD1G93A
transgenic animal models (Additional file 1: Table S1(2–7):
cross-sectional and longitudinal analysis; Additional file 1:
Table S4: cross-sectional analysis between SOD1G93A
transgenic animals and Wild type littermates).
Pathway enrichment
To avoid redundancy, only those pathways with the
highest enrichment values were shown when multiple
closely related pathways were identified by FAT. The
list of selected pathways is presented in descending
order of statistical significance (Fig. 2). In the early
stage (Fig. 2a), the strongest differential expression
between fast and slow progressing ALS patients was
related to proteins involved in ER to Golgi
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anterograde and retrograde transport, programmed
cell death, the immune response linked to MHCII
antigen presentation and to pathogenic Escherichia
coli infection. Pathways found to be regulated in
both late stage and earlier time point plasma sam-
ples included cell cycle (mitosis), apoptosis, protein
degradation, post-translational modifications and
folding, parkin-ubiquitin proteasome system, organ-
elle maintenance and membrane transport linked
pathways (organelle biogenesis and maintenance,
phagosome, and translocation of glucose transporter
4 (GLUT4) to the plasma membrane; Fig. 2b). Path-
ways showing significant enrichment only at the later
time point included cellular responses to stress, sen-
escence, vesicular transport, RHO GTPases, RNA
regulatory and metabolic processes (Fig. 2c).
When the slow and fast progressing ALS patients were
analysed separately and longitudinally (Fig. 3), the most
enriched pathways in slow progressors (Fig. 3a) included
DNA damage and telomere stress induced senescence,
inflammation and metabolism. In fast progressing ALS pa-
tients (Fig. 3c), changes in signal transduction and
parkin-ubiquitin proteasome system pathways were among
the most enriched, followed by a cluster of five different
pathways sharing a role in the immune response, RNA
regulation and protein transport. Notably, in common with
the cross-sectional study, the longitudinal analysis identified
regulation of proteins involved in cell cycle and signalling,
Rho GTPase, membrane trafficking, organelle mediated
transport and translocation of GLUT4 to the plasma mem-
brane (Fig. 3b).
Gene ontology (GO) biological processes
In the cross-sectional study, cytoskeleton organization
was found enriched in both early and late time points
while phagocytosis, epidermis development, membrane
organization, innate immune response, ageing and cell
division were among the most enriched biological pro-
cesses only in the early time point. In the late time point,
regulation of endopeptidase activity was the top enriched
Fig. 1 Distribution of differentially regulated features and ALS patient phenotypic variants: (a) Principal component analysis (PCA) using scores
plots before feature selection (colour codes: fast-early: yellow; fast-late: green; slow-early: red; slow-late: brown). The disease stage dimension is
the main contributor to the separation in the first component (35.86%) and the rate of disease progression is the main contributor to the
separation on the second component (15%). b PCA loadings plot generated with data derived from regulated features shows a more significant
separation in the first compared to second component (40.6% and 17.5% respectively). c Volcano plot showing significantly regulated features
comparing fast and slow progressing ALS patients in the early time point (cross-sectional study). d Volcano plot showing significantly regulated
features comparing early and late time points for the slow progressing ALS patients (longitudinal study). Volcano plots agree with PCA showing a
more significant difference between early and late time points when compared to fast versus slow disease progression
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term along with fibrinolysis and proteolysis (Additional
file 1: Figure S3).
In the longitudinal study and in the fast progressing
ALS patients, proteins involved in cytoskeletal
organization, folding and stabilization, cell adhesion,
negative regulation of endopeptidase activity, innate im-
mune response and substantia nigra development were
within the most significantly enriched biological features
(Additional file 1: Figure S3B). The analysis of the early
versus late time points in the slow progressing patients
did not show any significantly enriched biological
process.
Regulated protein candidates
The early disease time point was chosen as the source of
most informative differentially expressed plasma protein
candidates when comparing ALS-Fast versus ALS-Slow
(Table 2; proteins containing two or more peptides
shown in a top-down order of fold-changes). Additional
file 1, Table 1 shows the most regulated proteins com-
paring fast versus slow ALS patients in late disease (1),
early versus late time points in both fast (2) and Slow (3)
progressing ALS patients, as well as those identified in
the same cross-sectional (4–5) and longitudinal (6–7)
experiment in animal models. The most regulated pro-
teins emerging from the comparison of pre-symptomatic
and symptomatic SOD1G93A transgenic mice with their
related genetic back-ground WT littermates are reported
in Additional file 1: Table S3.
Plasma proteomic profile in fast vs slow SOD1 G93A
mouse models of ALS and comparability with human
pathology
Functional analysis for enriched pathways and biological
processes (GO terms) in the plasma proteome from the
ALS animal models was performed in the same way as
for human cases (Additional file 1: Table S2). Enriched
features were compared with those seen in the human
arm of the study. There was only a partial overlap in
enriched pathways between the human and mouse
proteome changes comparing data from the different
time points in the two species. Chaperonin mediated
protein folding and mitotic processes (pre-symptomatic
mouse model, early and late human ALS; Fig. 4a); RHO
GTPase activators of IQGAPs (symptomatic mouse
model, late human ALS) and apoptosis, anchoring of the
basal body to the plasma membrane and AURKA Acti-
vation by TPX2 (symptomatic mouse model, early hu-
man ALS) (Fig. 4c) were among the pathways shared by
human and mouse ALS.
However, four pathways; assembly of the primary
cilium, organelle biogenesis and maintenance, regulation
of PLK1 Activity at G2/M transition and translocation of
GLUT4 to the plasma membrane were found enriched
A B C
Fig. 2 Functional analysis of the proteomic data obtained comparing data from fast versus slow progressing ALS patients. The cross-sectional
analysis was based on the list of regulated proteins (FC 1.3, p value < 0.05). Pathways with a p value < 0.05 were considered significantly enriched
and–plotted with a -log 10 transformed p value. Functional analysis was performed for Reactome pathways, if not otherwise specified. Only the
pathways with the highest enrichment were reported among the selected redundant pathways (mostly cell cycle and mitosis (early) and RHO
GTPase (late)). Significantly enriched pathways in the early stage (a), late stage (c) and in both time points (b)
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in both animal models and human disease at all stages
considered (Fig. 4a, c).
With regards to biological processes, cytoskeleton
organization was the only feature enriched when com-
paring fast versus slow plasma proteomes from animal
and human at the early and late time points (Fig. 4b, d).
The acute-phase response GO term was consistently
enriched in the pre-symptomatic and symptomatic
mouse proteome, but only enriched in the late stage of
human disease. The dysregulation of proteolysis pathway
was observed only at the late stage in both species.
Phagocytosis engulfment was shared between the human
early and the symptomatic mouse time points (Fig. 4d).
Immunodetection studies
Using immunodetection, we have re-tested the plasma
expression of protein candidates belonging to the regu-
lated pathways identified by plasma TMT proteomic
analysis in ALS patients and in SOD1G93A transgenic
mice, including metabolic processes (APOE, APOA1),
acute response, inflammation and cell senescence
(ITGB3, Galectin-3, TGFB1). These proteins appear also
as regulated in the proteomic analysis comparing WT
and SOD1G93A transgenic mice in both genetic
back-grounds (Additional file 1: Table S5). The re-test
experiment was performed using plasma samples from
the ALS patients of the discovery cohort (n = 12), ALS
from a re-test cohort (n = 47) and from healthy controls
(n = 29; Table 1) as well as plasma samples from
WT129Sv, Pre-SOD1129Sv, Sym-SOD1129Sv, WTC57,
Pre-SOD1C57 and Sym-SOD1C57 mice (n = 36, 6 per
sub-group).
ALS patients: APOE was up-regulated in plasma from
ALS-Fast compared to ALS-Slow and healthy controls
(p = 0.035 and p = 0.041 respectively; Fig. 5a). Regression
analysis showed a modest correlation between APOE
plasma levels and PRL (p = 0.041; Fig. 5a1). Kaplan
Mayer analysis identified reduced survival in the higher
APOE tertile compared to middle and lower tertiles (p =
0.0156; Fig. 5a2) while evaluation of diagnostic perform-
ance by receiver operating characteristic (ROC) analysis
showed that APOE levels separated ALS-Fast from
ALS-Slow (Area: 0.6759; Std. Error = 0.07162; p = 0.0204;
Fig. 5a3).
APOE analysis in plasma from the discovery cohort
(n = 12) showed a trend of over-expression in ALS-fast
compared to ALS slow which did not reach significance
(data not shown; p = 0.069). There was no statistically
Fig. 3 Functional analysis of the proteomic data obtained comparing early versus late disease stage. The longitudinal analysis was undertaken
using the list of total regulated proteins (FC 1.3, p value < 0.05) in slow and fast progressing ALS individuals independently. Pathways with a p
value < 0.05 were considered significantly enriched and plotted with a - log 10 transformed p value in descending order of statistical significance.
Functional analysis was performed for Reactome pathways, if not otherwise specified. Only pathways with the highest enrichment were reported
among redundant pathways. Significantly enriched pathways in slow progressing patients (a), in fast progressing patients (c) and shared by slow
and fast progressing patients (b)
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significant regulation of Galectine-3, TGFb1, ApoA1 and
ITGB3 plasma levels at group analysis comparing healthy
controls to ALS-FAST and ALS-Slow in both discovery
and re-test cohorts, although a trend of up-regulation in
ALS-Fast compared to ALS-Slow was seen in both co-
horts for these protein candidates (data not shown).
ITGB3 and Galectin-3 WB analysis was performed on
plasma samples from the discovery and re-test cohort,
including ALS-Fast (n = 12), ALS-Slow (n = 2) and
healthy controls (n = 10). WB showed a trend of
up-regulation for both Galectin-3 and ITGB3 in
ALS-Fast compared to ALS-slow which was not signifi-
cant (data not shown). These results are in line but not
in complete agreement with the level of differential
regulation seen in the proteomic experiment of the early
and late time points (ITGB3 adjusted p value = 0.001111;
Galectin adjusted p value = 0.002369; Table 2, Additional
file 1: Table S1).
SOD1G93A transgenic mice: ITGB3 was significantly
up-regulated in plasma from pre-symptomatic
SOD1G93A transgenic mice of both fast (129S) and
slow (C57) genetic backgrounds compared to both WT
Table 2 Regulated proteins in fast compared to slow progressing ALS patients in the early disease stage












P05106 Integrin beta-3 ITGB3 2 2.224407 0.001111
O95810 Serum deprivation-response protein SDPR 3 2.102 0.001403
H7BYX6 Isoform of P13591, Neural cell adhesion molecule 1 NCAM1 2 2.027403 0.000418
P04003 C4b-binding protein alpha chain C4BPA 7 2.013732 8.04E-05
P07437 Tubulin beta chain TUBB 2 1.908567 0.00790
P63173 60S ribosomal protein L38 RPL38 2 1.727873 0.00652
Q14697 Neutral alpha-glucosidase AB GANAB 2 1.638215 0.00134
P02649 Apolipoprotein E APOE 9 1.513701 8.53E-05
P36957 Dihydrolipoyllysine-residue succinyltransferase component of
2-oxoglutarate dehydrogenase complex, mitochondrial
DLST 2 1.487187 0.00960
A0A0A0MR02 Isoform of P45880, Voltage-dependent anion-selective channel
protein 2
VDAC2 4 1.4397 0.00229
P05090 Apolipoprotein D APOD 6 1.293627 0.00240
P80723 Brain acid soluble protein 1 BASP1 4 1.220442 0.00111
P15169 Carboxypeptidase N catalytic chain CPN1 3 1.17725 0.00616
Q06033–2 Isoform of Q06033, Isoform 2 of Inter-alpha-trypsin inhibitor
heavy chain H3
ITIH3 4 1.176924 0.00172
P48740–2 Isoform of P48740, Isoform 2 of Mannan-binding lectin serine
protease 1
MASP1 2 1.126878 0.00134
P35527 Keratin, type I cytoskeletal 9 KRT9 6 1.061453 0.00827
Q15582 Transforming growth factor-beta-induced protein ig-h3 TGFBI 3 1.026849 0.00652





P69905 Hemoglobin subunit alpha HBA1 6 −1.12687 0.00682
E7ETH0 Isoform of P05156, Complement factor I CFI 3 −1.14553 0.00190
O75636–2 Isoform of O75636, Isoform 2 of Ficolin-3 FCN3 4 −1.16238 0.00616
Q96IY4 Carboxypeptidase B2 CPB2 2 −1.23801 0.00134
P05452 Tetranectin CLEC3B 2 −1.32297 0.00173
P30050 60S ribosomal protein L12 RPL12 2 −1.50426 0.00172
P20700 Lamin-B1 LMNB1 2 −1.86089 0.00728
P00505 Aspartate aminotransferase, mitochondrial GOT2 2 −2.47293 0.00172
P02042 Hemoglobin subunit delta HBD 3 −2.49876 0.00040
Q5T123 Isoform of Q9H299, SH3 domain-binding glutamic acid-rich-
like protein 3
SH3BGRL3 2 −2.75577 0.0011
Only proteins identified with at least two unique peptides are shown. Up-regulated proteins are shown in the upper part of the table (grey), with Integrin beta-3
showing the highest fold change. Down-regulated proteins are shown in the bottom part of the table (light blue), with Isoform of Q9H299, SH3 domain-binding
glutamic acid-rich-like protein 3, showing the highest fold change of all down-regulated proteins
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and symptomatic mice (Fig. 5b; Pre-SOD1129Sv
p = 0.003, Pre-SOD157 p = 0.020). Within the same
genotypes, ITGB3 expression decreased significantly
in symptomatic SOD1G93A transgenic mice compared
to pre-symptomatic (Sym-SOD1C57 p = 0.013;
Sym-SOD1129S p = 0.039; Fig. 5b). Galectin-3 was
down-regulated in plasma from pre-symptomatic and
symptomatic SOD1G93A transgenic mice with fast gen-
etic background compared to their WT littermates
(Pre-SOD1129Sv p = 0.009; Sym-SOD1129Sv p = 0.004;
Fig. 5b1), but not in the slow progressing genetic
background (Fig. 5b1). TGFB1 plasma expression in-
creased significantly in pre-symptomatic and symptom-
atic slow SOD1G93A transgenic mice compared to their
WT littermates (Fig. 5b2: Pre-SOD157 p = 0.013;
Sym-SOD1C57 p = 0.001). Conversely, TGFB1 was
down-regulated in pre-symptomatic and symptomatic
fast SOD1G93A transgenic mice compared to their WT
littermates (Pre-SOD1129Sv p = 0.039; Sym-SOD1129S
p = 0.039). There was no statistically significant change
of APOE and APOA1 plasma expression between WT
and SOD1G93A transgenic mice of both genetic back-
grounds (data not shown). For all 5 protein candidates,
immunodetection supported the same pattern of expres-
sion found in proteomics.
Analysis of RNA expression of Galectin-3, TGFB1 and
ITGB3 in a range of cortical cells [28] showed predom-
inant microglia expression for all three proteins (Fig. 5c,
c1, c2 - http://www.brainrnaseq.org/).
Discussion
This study has three unique aspects: 1) a novel quan-
titative proteomics approach which combines tissue
and fluid in a single experiment using TMT® label-
ling and liquid chromatography combined to mass
spectrometry, 2) the use of PBMC, peripheral re-
porters of central neuro-inflammation [29] as source
tissue for plasma biomarkers identification and 3) the
inclusion of two species (human and mouse) where
ALS is linked to different disease causative factors:
multiple copies of mutated SOD1 transgenes in the
animal and not yet fully characterized genetic and
most probably environmental factors in human (none
of the patients carried one of the genetic mutations
so far identified in ALS).
We have observed that the rate of ALS progression,
and above all the disease stage, are linked to substantial
changes in the abundance of a wide range of plasma
proteins. In ALS patients and animal models, regulated
plasma proteins support a range of inflammatory events
Fig. 4 Human-animal model comparison of enriched pathways (a and c) and biological processes (b and d) derived from regulated proteins in
each specie. a Shows the pathways and (b) the biological processes that were found enriched in both the mouse model pre-symptomatic stage
and in the human ALS proteome at an early and a late disease stage respectively. c Shows the pathways and (d) the biological processes found
enriched in both the mouse model symptomatic stage and the human ALS proteome at an early and late disease stage respectively. Pathways
and biological processes, including translocation of GLUT4 to the plasma membrane or acute-phase response, that were found regulated in both
mouse model and human plasma proteome at all time points are indicated with an asterisk (*)
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and metabolic modifications, while senescence-related
alterations are mostly seen with the disease progression
in the human ALS proteome. Studying similar pheno-
typic variants in mouse models and patients with ALS,
we have identified only a partial overlap in the overall
plasma proteomes acquired in time points which may
not necessarily be comparable in the natural history of
the disease in humans and rodents. Furthermore, the
monogenetic driver of disease in an inbred animal model
may only partially reflect the pathological processes of
adaptation seen in sporadic human disease, explaining
this discrepancy. It is nevertheless encouraging that we
could dissect common features that could be developed
as translational biomarkers to bridge pre-clinical and hu-
man studies. These shared biological features appear to
be independent from those genetic and environmental
determinants driving the disease in humans and animals,
representing an ALS-specific signature and priority tar-
gets for any investigation into biomarkers and therapeu-
tics in both pre-clinical and clinical setting.
The cross-sectional proteomic studies in human and
animals were based on a relatively small sample size.
The risk of obtaining non-specific biological signals was
mitigated by the inclusion of phenotypic variants and
disease time points to test the longitudinal profile of the
disease, while a re-test experiment in larger cohorts of
WT and transgenic animals as well as of ALS patients
and healthy controls, helped to confirm the regulation of
relevant protein candidates observed using proteomics,
particularly in the mouse model. Further investigation of
the regulated immuno-metabolic and senescence path-
ways showed how plasma expression of APOE differenti-
ates ALS patients based on rate of disease progression,
while the study of other biomarkers like ITGB3,
Galectin-3 and TGFB1 confirmed the pattern of regula-
tion across WT and SOD1G93A transgenic animal
models seen in the proteomic experiment. Evidence of
Apolipoprotein E genotype being a determinant of age at
onset in ALS patients and in particular, of the ε4 allele









Fig. 5 Re-test of protein candidates using immunoassays. ELISA and Meso Scale Discovery (MSD) analysis of selected protein candidates in
plasma samples. a. APOE is up-regulated in plasma samples from ALS-Fast compared to ALS-Slow; a1: positive correlation between APOE plasma
levels and PRL in ALS patients; a2: reduced survival for ALS patient with higher APOE levels (above 70,776 pg/ml). a3: APOE levels separate ALS-
Fast from ALS-Slow b. ITGB3 is up-regulated in plasma from pre-symptomatic transgenic SOD1G93 animal models (Pre-SOD1129Sv, Pre-SOD1C57)
compared to related WT animals, while ITGB3 plasma expression in the respective symptomatic animals are significantly reduces to WT levels. b1
Galectin-3 is significantly downregulated in pre-symptomatic (Pre-SOD1129Sv) and symptomatic in fast progressing SOD1G93A transgenic mice
(Sym-SOD1129Sv) compared to 129Sv WT animals (WT129Sv). b2 TGFB1 is significantly upregulated in plasma from Pre-SOD1C57 and from Sym-
SOD1C57 compared to WTC57, while it down-regulated in Pre-SOD1129Sv and Sym-SOD1129Sv compared to WT129Sv. In each figure, reported
upper p-values relate to Kruskall-Wallis while lower p-values to Dunn’s multiple comparisons tests. c data mining using a RNA-Seq transcriptome
and splicing database of glia, neurons, and vascular cells of the cerebral cortex. This interactive splicing browser shows predominant microglia
expression of ITGB3 (c), Galectin-3 (c1) and (c2) TGFB1 (http://www.brainrnaseq.org/) in a range of cortical cells [28]. PRL: progression rate to last
visit. WT: wild type. OPC: oligodendrocyte precursor cells. FPKM: fragments per kilobase of transcript sequence per million mapped fragments
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expression particularly for the risk of bulbar-onset ALS
in men has been reported and discussed in the literature
[30] . From a biomarker perspective, APOE plasma
levels have also been correlated with both rate of deteri-
oration and survival [31].
The re-test study by immunodetection in ALS patients
did not show the same degree of regulation for ITG3,
Galectin-3 and TGFB1 shown in ALS-Fast compared to
ALS-Slow using deep proteomics. This can be explained
by the small sample size of the discovery cohort used in
the proteomic experiment and by the concomitant high
phenotypic (and genetic) variability of the disease in hu-
man. MS and antibody-based detection techniques have
also different analytical sensitivity and specificity, which
could also depend on the pre-analytical albumin deple-
tion utilized in proteomics but not in ELISA, as albu-
min’s chaperoning and protein-binding activity may
affect the abundance of specific proteins [32]. In the
more homogeneous animal models of ALS, proteomic
and immunodetection provided comparable results.
The plasma/PBMC proteome as a reporter of disease
progression in human ALS
PCA indicates that differences in the plasma proteome
are more significant between early and late stages of dis-
ease, independent of speed of progression (Fig. 1). The
selection of ALS patients in an “early” disease stage is
complicated by unavoidable diagnostic delays and by
poor detection of early signs of “phenoconversion” in
asymptomatic individuals. Therefore, in our study, par-
ticipants were enrolled and sampled at or shortly after
diagnosis, and re-sampled after an interval of 6 to 24
and of 48 to 56 months for fast and slow progressing
ALS patients respectively (fast and slow ALS patients
had comparable ALSFRS-R at the late stage). The
change of the plasma proteomic profile in this
time-frame includes the early activation of the innate
immune response (MCH II signalling), initiation of
apoptosis and dysfunction of the proteasome systems
which only partially overlap with the pre-symptomatic
mouse plasma proteome, while later alterations related
to metabolism and glucogenesis as well as RHO GTPase
activation are in common with the animal model prote-
ome (Fig. 2). In our study, RHO GTPase activity is
closely linked to a marked regulation of the cytoskeletal
proteins organization in both species. RHO GTPase
binding to plasma membrane-associated actin cytoskel-
eton is fundamental to maintain cell-cell and/or cell
extracellular matrix (ECM) adhesion [33]. The early im-
mune response activation in our plasma proteome en-
dorses previous reports of a systemic inflammatory
response in ALS, involving monocyte/macrophages and
a decrease of peripheral T-regulatory cells (Treg) par-
ticularly in fast progressing ALS patients, but may also
relate to those auto-immune disorders which are
co-morbid or precede ALS as previously reported [5, 17,
34–36]. However, none of the ALS cases in study had
such a history and their blood levels of acute phase reac-
tants, including CRP and ferritin, were within normal
limits.
The prominent expression of proteins involved in the
translocation of GLUT4 to the plasma membrane ob-
served in all disease stages under investigation in human
and mice, suggests an altered glucose uptake from the
blood-stream and a dysmetabolic state (Fig. 2). Lactate, a
by-product of cell metabolism which has been reported
as raised in blood and CSF from ALS patients, is critic-
ally involved in glucose utilization for energy production
[37–39]. Recently, it has been proposed that the adeno-
sine triphosphate (ATP)-dependent lactate flow between
muscle and neurons at the neuromuscular junction
(NMJ) may become disrupted in ALS [40]. Extracellular
lactate has been shown to cause T cell entrapment at
sites of inflammation by inhibition of CD4+ and CD8+
T cells motility, inducing chronic inflammation and a
switch of CD4+ T helper cells to a Th17 phenotype with
the release of pro-inflammatory cytokines [41]. Hence
lactate may facilitate chronic inflammation, a key feature
of neurodegeneration, while causing NMJ disruption and
motor neuron death. Lactate dyscrasia and translocation
of GLUT4 to plasma membrane have also been reported
to interfere with muscle contraction by loss of GTPase
activity [42–46]. The altered GLUT4 translocation and
lactate dyscrasia are among those features potentially
bridging human to animal pathology, representing a bio-
logically plausible biomarker and treatment target in
ALS.
Inflammation, cell senescence and microglial biomarkers
in ALS across species
When the differential plasma proteomic profiles of
pre-symptomatic and symptomatic transgenic animals
were compared to early and late ALS cases, we found
inter-species commonalities which included, among
others, changes in the acute phase and innate immune
responses, protein folding and GTPase Rho signalling
(Fig. 4). Further analysis of differentially regulated fea-
tures in our study pointed to microglia activation: 1) the
early up-regulation of proteins involved in apoptosis,
phagocytosis and of the proteasome system reflecting
microglia/macrophage activation which leads to removal
of cellular debris and protein aggregates by phagocytosis
[47] and 2) ITGB3, Galctin-3 and TGFB1 are selective
brain microglia markers, according to a large RNA-Seq
transcriptome and splicing database of glia, neurons,
and vascular cells of the cerebral cortex (http://
www.brainrnaseq.org/; Fig. 5, C,C1,C2).
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Integrins, Galectin-3 and TGFB1 have been implicated
in different biological processes including angiogenesis,
fibrosis and wound healing [48, 49]. These proteins are
also central to the development of the acute phase re-
sponse leading to chronic tissue injury [50], a molecular
feature shared by animal and human ALS plasma pro-
teomes. Critically, ITGB3 has been shown to be a key
factor in cell senescence and in the interplay between
membrane and ECM through a molecular cascade that
includes activation of TGFB1 [51]. Our study also show
activation of telomere stress induced senescence with
disease progression, implicating ITGB3 and TGB1 fur-
ther in replicative senescence, where telomere length be-
comes fundamental in loss of cellular homeostasis
observed with aging [52]. Astrocyte over-expression of
TGFB1accelerates disease progression in ALS mice [53].
ALS skeletal muscle and plasma also show enhanced
TGFB1signaling, which can lead to muscle fibrosis [54,
55]. The up-regulation of ITGB3 and TGFB1adds to our
previous finding of increased levels of pro-inflammatory
cytokines like IL-6 in plasma from ALS patients, a con-
certed response described as senescence-associated
secretory phenotype [6, 56–58]. These microglial targets
are ALS-specific as they seem relevant to both mouse
and human, where the disease is likely to follow different
pathological routes to arrive to the same end-point: the
loss of motor neurons.
ALS: Choosing the right therapeutic target and timing for
intervention
In humans, the lack of any means of accurate prognosti-
cation makes ALS clinical heterogeneity the main obs-
tacle to the development of effective treatments [34].
Conversely, in the relatively homogeneous SOD1 animal
models of ALS, phenotypic variations depend only on
expression levels of mutant SOD1, gender, genetic back-
ground and possibly on breeding conditions, all features
that can be manipulated in a controlled experimental
setting [59]. We therefore believe that any novel treat-
ment strategy for ALS will have to be tested in a more
personalized approach, using biomarkers and genetics
for clinical stratification [60]. If pre-clinical work is con-
templated like, for example, testing drug efficacy in a
mouse model, than it may be reasonable to choose the
molecular target of drug engagement among those
shared by the model and human pathology, so that
translation to ALS patients may have more chances to
succeed. This study offers insight into human-rodent
molecular pathways that could be at the center of future
treatment strategies for ALS.
Our study has shown a convergence between species
in molecular mechanisms which support the regulation
of the immune response and of cell metabolism. These
shared regulated pathways support the potential for early
immune-modulatory strategies, including the use of
anti-inflammatory compounds, stem-cell based
immune-effective treatment or protein kinase inhibitors,
used to stem microglia-mediated neuroinflammation
[21, 61, 62]. While fighting this innate immune response
as early as possible may be plausible, it is worth consid-
ering that macrophages at this stage and potentially
throughout the disease course clear debris from cells
undergoing degeneration. This “beneficial” inflammatory
response may later shift towards a chronic and harmful
process [6, 47, 63–67]. Therefore, timing of immunomo-
dulation in ALS is crucial and interventions must aim at
the window of therapeutic opportunity to arrest any de-
velopment to chronic inflammation, which is an integral
part of cell senescence and of the SASP response. In-
ducers of heat shock response have been shown to effi-
ciently inhibit and reduce chronic inflammation in
obesity and the same therapeutic paradigm may be rele-
vant in neuroinflammation [68].
Our findings support also treatment strategies which
target the enzymatic chain of glucose metabolism lead-
ing to the production of lactate, based on the combin-
ation of drugs that inhibit lactate accumulation at the
NMJ and its effect in reducing T-cell migratory capabil-
ities, enhancing respiratory chain function, and/or pro-
moting re-innervation [40]. Interestingly, nutritional
supplements acting at the interface between inflamma-
tion and metabolism have been shown to dampen the
inflammatory environment. For example, omega-3 es-
sential fatty acids decrease the levels of IL-1, IL-6, TNFα
and CRP [69] and improve cognitive function in aged
mice [70].
Conclusions
This study provides one of the most in-depth qualitative
and quantitative proteomics studies performed in ALS,
using the plasma/PBMC interface to investigate crucial
aspects of phenotypic heterogeneity of this condition
and across species. Researchers working on ALS and on
other neurodegenerative disorders will be able to draw
conclusions from the data we have generated to steer
the development of novel biomarkers and therapeutic
strategies in ALS.
Additional files
Additional file 1: Figure S1. represents and scheme of the workflow
followed to perform this study. Figure S2. shows the PCA before batch
effect correction, Figure S3. shows enriched biological processes for the
cross-sectional and longitudinal study. Table S1. shows the top regulated
proteins in plasma from 1) fast versus slow progressing ALS patients at
the late stage disease, early versus late time points for slow and fast pro-
gressing ALS patients and mouse model: cross sectional and longitudinal
studies. Table S2. where the functional analysis of the animal model
proteomic data are presented. Table S3. Presents the top regulated
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proteins in plasma from Wild type versus SOD1G93A transgenic mice at
the pre-symptomatic and symptomatic stage of disease, for both genetic
backgrounds under investigation. Table S4. contains the results for the
functional analysis for the proteomic study comparing wild type versus
transgenic ALS SOD1G93A mice. Table S5. Shows the proteomic data of
the immunosenescence protein candidates selected for the re-test experi-
ments. (DOCX 295 kb).
Additional file 2: Detailed protocols for Sample fractionation, LC-MS/MS
analysis and peptide identification and quantification: methods are ex-
plained in more detail in this additional file. (PDF 14 kb)
Additional file 3: contains all the raw data generated in the human
analysis. (CSV 495 kb)
Additional file 4: contains all the raw data generated in the animal
model analysis. (CSV 3617 kb)
Abbreviations
ALS: Amyotrophic lateral sclerosis; ALSFRS-R: Amyotrophic lateral sclerosis
Functional Rating Scale-Revised; CRP: C-reactive protein; ECM: Extracellular
matrix; EDTA: Ethylenediaminetetraacetic acid; ER: Endoplasmatic Reticulum;
FBS: Fetal bovine serum; FTD: Frontotemporal dementia; HRP: Horseradish
peroxidase; IL: Interleukin; ITGB3: Integrin Beta 3; LC-MS/MS: Liquid
chromatography tandem mass spectrometry; LIMMA: Linear models for
microarray data; logFC: Log2 fold changes; MHC: Major histocompatibility
complex; NMJ: Neuromuscular junction; PBMC: Peripheral Blood
Mononuclear Cells; PBS: Phosphate buffered saline; PCA: Principal
component analysis; PRL: Disease progression to last visit; PSM: Peptide
spectrum matches; RT: Room temperature; SASP: Senescence-associated
secretory phenotype; SCX: Strong Cation exchange; SOD1: Superoxide
dismutase 1; TBST: Tris buffered saline- tween; TCEP: Tris(2-carboxyethyl)
phosphine 10; TDP-43: TAR DNA-binding protein 43;
TEAB: Triethylammonium bicarbonate; TGF-β1: Transforming growth factor
beta 1; TMT: Tandem mass tag; TNFα: Tumor necrosis factor alpha
Acknowledgments
We acknowledge the patients and their families for kindly agreeing to
collaborate in this project, the authors would also like to thank Gitte Boehm
for her assistance on sample preparation for the animal model experiments,
other colleagues in Proteome Sciences in Frankfurt and Proteome Sciences
London, in particular Eva Sedlak and Richard Churchus for the mass
spectrometry data acquisition.
Funding
Motor Neurone Disease Association (Malaspina/Apr13/817–791). Wellcome
Trust support to a parallel study (Pathfinder Award, grant number 103208).
Availability of data and materials
All data generated or analysed during this study are included in this published
article and its supplementary information files as Additional files 1, 2, 3, 4.
Authors’ contributions
IZ is the lead author who has worked on the design, conduction of
experiments and analysis of the data and contributed to manuscript writing.
VL has performed all the Mesoscale assays and validation processes. MB and
VM were responsible for data processing, bioinformatics method
development and execution. MB has also developed the functional analysis
tool employed in this study. GN and CB have been in charge of breeding
and sampling of the animal model used in this study. RA, VL, OY and CHL
have worked on the human samples collection, processing and storage,
while contributing to sample selection, RA has also performed some of the
Integrin beta 3 western blot experiments. EL, MW, PY contributed to the
experimental design. AM and IP have conceived the study design and led
on all the aspects including bio banking, experimental procedures, data
interpretation and manuscript writing. AM was awarded he grant that has
made this study possible. LG has contributed to the project design and
supervision. AM was the group leader of this project leading on patient
recruitment, guidance, paper writing and study design. All authors read and
approved the final manuscript.
Ethics approval and consent to participate
Ethical approval was obtained from the East London and the City Research
Ethics Committee 1 (09/H0703/27). All participants provided written consent
to the study (or gave verbal permission for a carer to sign on their behalf).
Procedures involving animals and their care were conducted in conformity
with institutional guidelines that comply with national (Legislative Degree
26.03.2014) and international (EEC Council Directive 2010/63, August, 2013)
laws and policies. Animals studies were approved by the Mario Negri





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Neuroscience and Trauma Centre, Blizard Institute, Barts and The School of
Medicine and Dentistry, Queen Mary University of London, 4 Newark Street,
London, City of London, Greater London E1 2AT, UK. 2Proteome Sciences plc,
Hamilton House, Mabledon Place, London, UK. 3Laboratory of Molecular
Neurobiology, Department of Neuroscience, IRCCS - Istituto di Ricerche
Farmacologiche Mario Negri, Milan, Italy. 4Sobell Department of Motor
Neuroscience and Movement Disorders, MRC Centre for Neuromuscular
Disorders, UCL Institute of Neurology, University College London, London,
UK. 5Department of Neurology, China Medical University Hospital, Taichung
City, Taiwan.
Received: 4 January 2018 Accepted: 16 October 2018
References
1. Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor
BG. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler.
2009;10:310–23.
2. Baumer D, Talbot K, Turner MR. Advances in motor neurone disease. J R Soc
Med. 2014;107:14–21.
3. Ittner LM, Halliday GM, Kril JJ, Gotz J, Hodges JR, Kiernan MC. FTD and ALS--
translating mouse studies into clinical trials. Nat Rev Neurol. 2015;11:360–6.
4. Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20
years of failure. Are we any closer to registering a new treatment? Front
Aging Neurosci. 2017;9:68.
5. Henkel JS, Beers DR, Wen S, Rivera AL, Toennis KM, Appel JE, Zhao W,
Moore DH, Powell SZ, Appel SH. Regulatory T-lymphocytes mediate
amyotrophic lateral sclerosis progression and survival. EMBO Mol Med. 2013;
5:64–79.
6. Lu CH, Allen K, Oei F, Leoni E, Kuhle J, Tree T, Fratta P, Sharma N, Sidle K,
Howard R, et al. Systemic inflammatory response and neuromuscular
involvement in amyotrophic lateral sclerosis. Neurol Neuroimmunol
Neuroinflamm. 2016;3:e244.
7. Nardo G, Trolese MC, Bendotti C. Major histocompatibility complex I
expression by motor neurons and its implication in amyotrophic lateral
sclerosis. Front Neurol. 2016;7:89.
8. Marino M, Papa S, Crippa V, Nardo G, Peviani M, Cheroni C, Trolese MC,
Lauranzano E, Bonetto V, Poletti A, et al. Differences in protein quality
control correlate with phenotype variability in 2 mouse models of familial
amyotrophic lateral sclerosis. Neurobiol Aging. 2015;36:492–504.
9. Schmitt F, Hussain G, Dupuis L, Loeffler JP, Henriques A. A plural role for
lipids in motor neuron diseases: energy, signaling and structure. Front Cell
Neurosci. 2014;8:25.
10. Liu G, Fiala M, Mizwicki MT, Sayre J, Magpantay L, Siani A, Mahanian M,
Chattopadhyay M, La Cava A, Wiedau-Pazos M. Neuronal phagocytosis by
inflammatory macrophages in ALS spinal cord: inhibition of inflammation
by resolvin D1. Am J Neurodegener Dis. 2012;1:60–74.
11. Taylor JP, Brown RH Jr, Cleveland DW, Decoding ALS. From genes to
mechanism. Nature. 2016;539:197–206.
Zubiri et al. Molecular Neurodegeneration           (2018) 13:60 Page 15 of 17
12. Howlett DR. Protein Misfolding in disease: cause or response? Curr Med
Chem-Immunol, Endocri Metab Agents. 2003;3:371–83.
13. Edbauer D, Haass C. An amyloid-like cascade hypothesis for C9orf72 ALS/
FTD. Curr Opin Neurobiol. 2016;36:99–106.
14. Buchberger A, Bukau B, Sommer T. Protein quality control in the cytosol
and the endoplasmic reticulum: brothers in arms. Mol Cell. 2010;40:238–52.
15. Yin F, Sancheti H, Patil I, Cadenas E. Energy metabolism and inflammation in
brain aging and Alzheimer's disease. Free Radic Biol Med. 2016;100:108–22.
16. Ngo ST, Steyn FJ. The interplay between metabolic homeostasis and
neurodegeneration: insights into the neurometabolic nature of amyotrophic
lateral sclerosis. Cell Regen (London, England). 2015;4:5.
17. Malaspina A, Puentes F, Amor S. Disease origin and progression in
amyotrophic lateral sclerosis: an immunology perspective. Int Immunol.
2015;27:117–29.
18. Rossi S, Zanier ER, Mauri I, Columbo A, Stocchetti N. Brain temperature,
body core temperature, and intracranial pressure in acute cerebral damage.
J Neurol Neurosurg Psychiatry. 2001;71:448–54.
19. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O'Collins V,
Macleod MR. Can animal models of disease reliably inform human studies?
PLoS Med. 2010;7:e1000245.
20. Moujalled D, White AR. Advances in the development of disease-modifying
treatments for amyotrophic lateral sclerosis. CNS drugs. 2016;30:227–43.
21. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C,
Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, et al. Efficacy of
minocycline in patients with amyotrophic lateral sclerosis: a phase III
randomised trial. Lancet Neurol. 2007;6:1045–53.
22. Nardo G, Pozzi S, Pignataro M, Lauranzano E, Spano G, Garbelli S, Mantovani
S, Marinou K, Papetti L, Monteforte M, et al. Amyotrophic lateral sclerosis
multiprotein biomarkers in peripheral blood mononuclear cells. PLoS One.
2011;6:e25545.
23. Filareti M, Luotti S, Pasetto L, Pignataro M, Paolella K, Messina P, Pupillo E,
Filosto M, Lunetta C, Mandrioli J, et al. Decreased levels of Foldase and
chaperone proteins are associated with an early-onset amyotrophic lateral
sclerosis. Front Mol Neurosci. 2017;10:99.
24. Russell CL, Heslegrave A, Mitra V, Zetterberg H, Pocock JM, Ward MA, Pike I.
Combined tissue and fluid proteomics with tandem mass tags to identify low-
abundance protein biomarkers of disease in peripheral body fluid: an
Alzheimer’s disease case study. Rapid Commun Mass Spectrom. 2017;31:153–9.
25. Nardo G, Trolese MC, Tortarolo M, Vallarola A, Freschi M, Pasetto L, Bonetto
V, Bendotti C. New insights on the mechanisms of disease course variability
in ALS from mutant SOD1 mouse models. Brain Pathol. 2016;26:237–47.
26. Pizzasegola C, Caron I, Daleno C, Ronchi A, Minoia C, Carri MT, Bendotti C.
Treatment with lithium carbonate does not improve disease progression in two
different strains of SOD1 mutant mice. Amyotroph Lateral Scler. 2009;10:221–8.
27. Brooks BR. Functional scales: summary. Amyotroph Lateral Scler Other
Motor Neuron Disord. 2002;3(Suppl 1):S13–8.
28. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani
HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing
transcriptome and splicing database of glia, neurons, and vascular cells of
the cerebral cortex. J Neurosci. 2014;34:11929–47.
29. Koncarevic S, Lossner C, Kuhn K, Prinz T, Pike I, Zucht HD. In-depth profiling
of the peripheral blood mononuclear cells proteome for clinical blood
proteomics. Int J Proteomics. 2014;2014:129259.
30. Jawaid A, Poon M, Strutt AM, Rice LK, McDowell EJ, Salamone AR, Qureshi SU,
Simpson E, Appel SH, York MK, Schulz PE. Does apolipoprotein E genotype
modify the clinical expression of ALS? Eur J Neurol. 2011;18:618–24.
31. Lacomblez L, Doppler V, Beucler I, Costes G, Salachas F, Raisonnier A, Le
Forestier N, Pradat PF, Bruckert E, Meininger V. APOE: a potential marker of
disease progression in ALS. Neurology. 2002;58:1112–4.
32. Finn TE, Nunez AC, Sunde M, Easterbrook-Smith SB. Serum albumin
prevents protein aggregation and amyloid formation and retains
chaperone-like activity in the presence of physiological ligands. J Biol Chem.
2012;287:21530–40.
33. Govek EE, Newey SE, Van Aelst L. The role of the rho GTPases in neuronal
development. Genes Dev. 2005;19:1–49.
34. Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, McGrath M, Manfredi G,
Maragakis N, Miller RG, Pullman SL, et al. Mechanisms, models and
biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler
Frontotemporal Degener. 2013;14(Suppl 1):19–32.
35. Rentzos M, Rombos A, Nikolaou C, Zoga M, Zouvelou V, Dimitrakopoulos A,
Alexakis T, Tsoutsou A, Samakovli A, Michalopoulou M, Evdokimidis J.
Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal
fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol
Scand. 2010;122:425–9.
36. Bowerman M, Vincent T, Scamps F, Perrin FE, Camu W, Raoul C.
Neuroimmunity dynamics and the development of therapeutic strategies
for amyotrophic lateral sclerosis. Front Cell Neurosci. 2013;7:214.
37. Zaid H, Antonescu CN, Randhawa VK, Klip A. Insulin action on glucose
transporters through molecular switches, tracks and tethers. Biochem J.
2008;413:201–15.
38. Medina RA, Southworth R, Fuller W, Garlick PB. Lactate-induced
translocation of GLUT1 and GLUT4 is not mediated by the phosphatidyl-
inositol-3-kinase pathway in the rat heart. Basic Res Cardiol. 2002;97:168–76.
39. Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, Liu Y,
Tsingalia A, Jin L, Zhang P-W, et al. Oligodendroglia metabolically support
axons and contribute to neurodegeneration. Nature. 2012;487:443–8.
40. Vadakkadath Meethal S, Atwood CS. Lactate dyscrasia: a novel explanation
for amyotrophic lateral sclerosis. Neurobiol Aging. 2012;33:569–81.
41. Haas R, Cucchi D, Smith J, Pucino V, Macdougall CE, Mauro C. Intermediates
of metabolism: from bystanders to Signalling molecules. Trends Biochem
Sci. 2016;41:460–71.
42. Leney SE, Tavare JM. The molecular basis of insulin-stimulated glucose
uptake: signalling, trafficking and potential drug targets. J Endocrinol. 2009;
203:1–18.
43. Bogan JS, Kandror KV. Biogenesis and regulation of insulin-responsive
vesicles containing GLUT4. Curr Opin Cell Biol. 2010;22:506–12.
44. Foley K, Boguslavsky S, Klip A. Endocytosis, recycling, and regulated
exocytosis of glucose transporter 4. Biochemistry. 2011;50:3048–61.
45. Hoffman NJ, Elmendorf JS. Signaling, cytoskeletal and membrane mechanisms
regulating GLUT4 exocytosis. Trends Endocrinol Metab. 2011;22:110–6.
46. Kandror KV, Pilch PF. The sugar is sIRVed: sorting Glut4 and its fellow
travelers. Traffic (Copenhagen, Denmark). 2011;12:665–71.
47. Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer's disease.
Nat Immunol. 2015;16:229–36.
48. Margadant C, Sonnenberg A. Integrin-TGF-beta crosstalk in fibrosis, cancer
and wound healing. EMBO Rep. 2010;11:97–105.
49. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and
therapeutic opportunities. Nat Rev Cancer. 2010;10:9–22.
50. Gawlik KI, Holmberg J, Svensson M, Einerborg M, Oliveira BM, Deierborg T,
Durbeej M. Potent pro-inflammatory and pro-fibrotic molecules,
osteopontin and galectin-3, are not major disease modulators of laminin
alpha2 chain-deficient muscular dystrophy. Sci Rep. 2017;7:44059.
51. Rapisarda V, Borghesan M, Miguela V, Encheva V, Snijders AP, Lujambio A,
O'Loghlen A. Integrin Beta 3 regulates cellular senescence by activating the
TGF-beta pathway. Cell Rep. 2017;18:2480–93.
52. Victorelli S, Passos JF. Telomeres and cell senescence - size matters not.
EBioMedicine. 2017;21:14–20.
53. Endo F, Komine O, Fujimori-Tonou N, Katsuno M, Jin S, Watanabe S, Sobue G,
Dezawa M, Wyss-Coray T, Yamanaka K. Astrocyte-derived TGF-beta1
accelerates disease progression in ALS mice by interfering with the
neuroprotective functions of microglia and T cells. Cell Rep. 2015;11:592–604.
54. Gonzalez D, Contreras O, Rebolledo DL, Espinoza JP, van Zundert B, Brandan
E. ALS skeletal muscle shows enhanced TGF-beta signaling, fibrosis and
induction of fibro/adipogenic progenitor markers. PLoS One. 2017;12:
e0177649.
55. Houi K, Kobayashi T, Kato S, Mochio S, Inoue K. Increased plasma TGF-beta1
in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2002;106:
299–301.
56. Freund A, Orjalo AV, Desprez PY, Campisi J. Inflammatory networks during
cellular senescence: causes and consequences. Trends Mol Med. 2010;16:
238–46.
57. Chinta SJ, Woods G, Rane A, Demaria M, Campisi J, Andersen JK. Cellular
senescence and the aging brain. Exp Gerontol. 2015;68:3–7.
58. Ovadya Y, Krizhanovsky V. Senescent cells: SASPected drivers of age-related
pathologies. Biogerontology. 2014;15:627–42.
59. Pfohl SR, Halicek MT, Mitchell CS. Characterization of the contribution of
genetic background and gender to disease progression in the SOD1 G93A
mouse model of amyotrophic lateral sclerosis: a meta-analysis. J
Neuromuscul Dis. 2015;2:137–50.
60. Picher-Martel V, Valdmanis PN, Gould PV, Julien JP, Dupre N. From animal
models to human disease: a genetic approach for personalized medicine in
ALS. Acta Neuropathol Commun. 2016;4:70.
Zubiri et al. Molecular Neurodegeneration           (2018) 13:60 Page 16 of 17
61. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori
JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S. Safety and
immunological effects of mesenchymal stem cell transplantation in patients
with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;
67:1187–94.
62. Lee SH, Suk K. Emerging roles of protein kinases in microglia-mediated
neuroinflammation. Biochem Pharmacol. 2017;146:1-9. https://doi.org/10.
1016/j.bcp.2017.06.137. Epub 2017 Jul 4.
63. Bronzuoli MR, Iacomino A, Steardo L, Scuderi C. Targeting
neuroinflammation in Alzheimer’s disease. J Inflamm Res. 2016;9:199–208.
64. Krauthausen M, Saxe S, Zimmermann J, Emrich M, Heneka MT, Muller M. CXCR3
modulates glial accumulation and activation in cuprizone-induced demyelination
of the central nervous system. J Neuroinflammation. 2014;11:109.
65. Pal R, Tiwari PC, Nath R, Pant KK. Role of neuroinflammation and latent
transcription factors in pathogenesis of Parkinson’s disease. Neurol Res.
2016;38:1111–22.
66. Dibaj P, Steffens H, Zschuntzsch J, Nadrigny F, Schomburg ED, Kirchhoff F,
Neusch C. In Vivo imaging reveals distinct inflammatory activity of CNS
microglia versus PNS macrophages in a mouse model for ALS. PLoS One.
2011;6:e17910.
67. Hornik TC, Vilalta A, Brown GC. Activated microglia cause reversible
apoptosis of pheochromocytoma cells, inducing their cell death by
phagocytosis. J Cell Sci. 2016;129:65–79.
68. Newsholme P, de Bittencourt PI Jr. The fat cell senescence hypothesis: a
mechanism responsible for abrogating the resolution of inflammation in
chronic disease. Curr Opin Clin Nutr Metab Care. 2014;17:295–305.
69. Simopoulos AP. Omega-3 fatty acids in inflammation and autoimmune
diseases. J Am Coll Nutr. 2002;21:495–505.
70. Cutuli D, De Bartolo P, Caporali P, Laricchiuta D, Foti F, Ronci M, Rossi C,
Neri C, Spalletta G, Caltagirone C, et al. N-3 polyunsaturated fatty acids
supplementation enhances hippocampal functionality in aged mice. Front
Aging Neurosci. 2014;6:220.
Zubiri et al. Molecular Neurodegeneration           (2018) 13:60 Page 17 of 17
